ASX Announcements
Market Sensitive
Preliminary results from SCENESSE adolescent EPP study
Progress Report
- Feb 10, 2025
- 3 pages
Market Sensitive
Health Canada validates SCENESSE New Drug Submission
Progress Report
- Dec 23, 2024
- 2 pages
October 2022
Arnold Bloch Leibler back in proxy wars
Ownership Matters has recommended shareholders vote against the re-election of Clinuvel director Brenda Shanahan.
- Joe Aston
April 2022
Dutch court rejects investigation into Clinuvel chairman
An estranged former business partner of the biotech chairman recently petitioned a Dutch court in a last-ditch attempt to ensnare the wealthy businessman in a criminal probe.
- Carrie LaFrenz
- Investigation
- White collar crime
Clinuvel chairman faces bid to ensnare him in criminal probe
Willem Blijdorp, chairman of the ASX-listed biotech and one of the Netherlands’ wealthiest entrepreneurs, is accused of extortion and forgery relating to Iranian marble quarries.
- Carrie LaFrenz
November 2021
Clinuvel narrowly misses second strike on pay
Chairman Willem Blijdorp was successful in his urging of shareholders to back the board, but the biotech still suffered a very high protest vote.
- Carrie LaFrenz
Clinuvel facing second strike, possible board spill
Proxy firm Ownership Matters told clients to vote against the remuneration report but also against a board spill.
- Updated
- Carrie LaFrenz
September 2021
Clinuvel chief Philippe Wolgen’s extraordinary pay cheque
For the second year running, the CEO’s cash take alone has equated to more than 5 per cent of the drug company’s annual revenues.
- Myriam Robin
August 2020
Clinuvel board praises "unusual, amazing" CEO Philippe Wolgen
The Clinuvel board reckons CEO Philippe Wolgen is "of a different calibre". We don't disagree.
- Joe Aston
November 2019
- Opinion
- Investing
Looking for the next CSL? Be vigilant, because bubbles abound
Fuelled by buoyant sentiment, it’s natural for astute investors to search for the next Australian hero, but beware adventures in biotech investing.
- Jun Bei Liu
October 2019
Don't make a Scenesse but Wolgen stands to get $48m in rights
If shareholders are generous and Clinuvel's current growth trajectory keeps up, Dr Phillippe Wolgen stands to make millions.
- Myriam Robin
Clinuvel Pharmaceuticals surges to $2.2b after FDA tick
The surge added more than $800 million to Clinuvel's market value in a day, making the company one of the top 150 listed companies in Australia.
- Carrie LaFrenz
April 2019
- Investigation
- Biotech
The strange rise of Clinuvel Pharmaceuticals
The once minnow has ballooned to a $1 billion market value. Its path features an FBI-wanted man, a near collapse and the trials of getting drugs approved.
- Carrie LaFrenz
March 2019
Rich Bosses 2019: Meet Australia's 10 wealthiest executives
The chief executive from one of Australia's most consistent tech companies has delivered the best returns on 2019's Rich Bosses list.
- Updated
- James Thomson
January 2015
Low Aussie dollar could spur biotech takeovers
A string of high-profile setbacks may have whittled away support for biotechnology companies, but executives and analysts say there is still plenty of money from overseas and the weak Australian dollar may spur a series of takeovers by foreign buyers.
- Updated
- Jessica Gardner
March 2010
Company briefs
Australian goldminer Haoma Mining said it will buy back BHP Billiton’s 10 million Haoma shares for 10¢ each. On February 19 BHP advised Haoma it wished to sell the shares as part of the strategy of selling non-core assets.
Brief: Clinuvel Pharmaceuticals
The US Food and Drug Administration has agreed for Clinuvel Pharmaceuticals to proceed under its Investigational New Drug to conduct a Phase II clinical trial to evaluate afamelanotide as a first-in-class photoprotective drug in patients diagnosed with erythropoietic protoporphyria, a metabolic disorder characterised by absolute intolerance to light.
December 2009
Clinuvel (CUV)
Shares in biopharmaceutical company Clinuvel have recently benefited from positive preliminary results in its phase three porphyria trial.
- Updated
- Joyce Moullakis
Biotech on track for maiden profit
Clinuvel Pharmaceuticals may not be as close to commercialising its technology compared to some of its peers, but all signs indicate that the photo-protective drug developer is on track to turn in a maiden profit in 2011-12.
- Brendon Lau